Real world data reveal persistent gaps in long term IBD control

Real world data reveal persistent gaps in long term IBD control Real-world data and late-stage trial results at DDW 2026 highlight persistent gaps in long-term IBD control despite therapeutic advances. Written byBree Foster, PhD https://www.drugdiscoverynews.com/real-world-data-reveal-persistent-gaps-in-long-term-ibd-control-17158 Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic, relapsing inflammatory condition of the gastrointestinal tract associated with a growing global health burden. Patients with IBD are known to have distressing and severe physical symptoms such as abdominal pain, diarrhea, fecal urgency, fatigue, weight loss, and rectal bleeding. This can be debilitating, profoundly impacting a person’s social life and mental well-being.